Compugen (CGEN) Price & Analysis

Compare

1,010 Followers

CGEN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.13 - $2.66

Previous CloseN/A

Volume276.40K

Average Volume (3M)212.38K

Market Cap

$138.40M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)87.5

Beta1.71

Next Earnings

Aug 06, 2025

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding93,512,985

10 Day Avg. Volume243,020

30 Day Avg. Volume212,381

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$7.00

Price Target Upside382.76% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Long-term ValuationPotential single-digit royalties and milestones from AZN’s Fc-silent TIGIT x PD-1 bispecific rilvegostomig supports a positive long-term valuation for Compugen.

Pharmaceutical DevelopmentAZN continues to aggressively initiate Ph 3 studies with rilvegostomig, increasing the probability that Compugen will receive royalties from this program.

Price Target RevisionThe price target has been revised to $10 from $7, reiterating an outperform (OP) rating.

Bears Say

Trial OutcomesSignificant CGEN upside or downside is tied to Arcus and Gilead’s earlier Ph 3 trials of their Fc-silent TIGIT in gastric and lung cancers.

Compugen News

Compugen begins dosing in ovarian cancer trial

Compugen (CGEN) announced that the first patient was dosed in the global randomized sub-trial 1 of adaptive platform...

13d ago

CGEN

Compugen’s COM701 Trial: A New Hope for Ovarian Cancer?

Compugen (($CGEN)) announced an update on their ongoing clinical study. Compugen Ltd is currently recruiting participants for a...

8d ago

CGEN

Compugen Initiates Global Trial for COM701 in Ovarian Cancer

Compugen ( ($CGEN) ) has shared an update. On July 21, 2025, Compugen Ltd. announced the dosing of...

13d ago

CGEN

Compugen’s COM701 Trial: A Potential Game-Changer in Ovarian Cancer Treatment?

Compugen (($CGEN)) announced an update on their ongoing clinical study. Compugen Ltd is conducting a clinical trial titled...

15d ago

CGEN

Compugen’s Long-Term Value Potential: Buy Rating Backed by AstraZeneca Partnerships and Financial Stability

In a report released on May 20, Daina Graybosch from Leerink Partners maintained a Buy rating on Compugen...

2M ago

CGEN

Compugen’s Q1 2025: Clinical Progress and Financial Stability

Compugen ( ($CGEN) ) has released its Q1 earnings. Here is a breakdown of the information Compugen presented...

2M ago

CGEN

Compugen’s Earnings Call: Strategic Shifts and Clinical Advances

Compugen (($CGEN)) has held its Q1 earnings call. Read on for the main highlights of the call. The...

3M ago

CGEN

Compugen Reports Q1 2025 Results and Strategic Developments

Compugen ( ($CGEN) ) just unveiled an update. On May 19, 2025, Compugen Ltd. reported its first quarter...

3M ago

CGEN

Options Volatility and Implied Earnings Moves Today, May 19, 2025

Today, several major companies are expected to report earnings: CBAK Energy Technology (CBAT), Compugen (CGEN), Trip.com Group Sponsored...

3M ago

GSL

NIU

CGEN Earnings this Week: How Will it Perform?

Compugen (CGEN) is scheduled to report 1st quarter earnings on 05/19/2025, before the market opens. Regarding Q1 estimates,...

3M ago

CGEN

Compugen Announces Leadership Changes Effective September 2025

Compugen ( ($CGEN) ) has provided an update. On May 13, 2025, Compugen Ltd. announced significant leadership transitions...

3M ago

CGEN

Compugen appoints Eran Ophir as CEO, announces leadership transitions

Compugen (CGEN) announced leadership transitions to take effect in September 2025 following the Annual General Meeting. Anat Cohen-Dayag,...

3M ago

CGEN

Compugen reports Q4 EPS (7c) vs. 11c last year

Reports Q4 revenue $1.5M, consensus $17.47M. Expects current cash will be sufficient to fund its operating plans into...

5M ago

CGEN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

ARDX

CGEN

CGEN FAQ

What was Compugen’s price range in the past 12 months?

Compugen lowest stock price was $1.13 and its highest was $2.66 in the past 12 months.

What is Compugen’s market cap?

Compugen’s market cap is $138.40M.

When is Compugen’s upcoming earnings report date?

Compugen’s upcoming earnings report date is Aug 06, 2025 which is in 3 days.

How were Compugen’s earnings last quarter?

Compugen released its earnings results on May 19, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.025.

Is Compugen overvalued?

According to Wall Street analysts Compugen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Compugen pay dividends?

Compugen does not currently pay dividends.

What is Compugen’s EPS estimate?

Compugen’s EPS estimate is -0.06.

How many shares outstanding does Compugen have?

Compugen has 93,512,985 shares outstanding.

What happened to Compugen’s price movement after its last earnings report?

Compugen reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Compugen?

Currently, no hedge funds are holding shares in CGEN

Compugen Stock Smart Score

Neutral

Fundamentals

Return on Equity

-24.22%

Trailing 12-Months

Asset Growth

1.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Compugen

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on the field of immuno-oncology. Headquartered in Israel, Compugen leverages its proprietary computational discovery platforms to identify novel drug targets and develop therapeutic antibodies. The company's core products include a pipeline of immune checkpoint inhibitors designed to harness the body's immune system to fight cancer.

Compugen (CGEN) Earnings & Revenues

CGEN Earnings Data >

CGEN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a strategic shift in leadership, strong financial health, and promising clinical advancements, particularly with AstraZeneca. However, revenue decline and challenges in the TIGIT space were noted.Read More>

CGEN Stock 12 Month Forecast

Average Price Target

$7.00

▲(382.76%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,2.1538461538461537,2.8076923076923075,3.4615384615384617,4.115384615384615,4.769230769230769,5.423076923076923,6.076923076923077,6.730769230769231,7.384615384615385,8.038461538461538,8.692307692307693,9.346153846153847,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.9230769230769231,2.3461538461538463,2.769230769230769,3.1923076923076925,3.6153846153846154,4.038461538461538,4.461538461538462,4.884615384615385,5.3076923076923075,5.730769230769231,6.153846153846154,6.576923076923077,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.6923076923076923,1.8846153846153846,2.076923076923077,2.269230769230769,2.4615384615384617,2.653846153846154,2.8461538461538463,3.0384615384615383,3.230769230769231,3.4230769230769234,3.6153846153846154,3.807692307692308,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.76,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >